NCT07018323 - A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Graves' Disease

Interventions

DRUG

IMVT-1402

Dose 1 for 26 weeks

DRUG

IMVT-1402

Dose 2 for 26 weeks

DRUG

Placebo

For 26 weeks

Trial Locations (22)

10022

RECRUITING

Site Number - 1009, New York

23510

RECRUITING

Site Number - 1016, Norfolk

27577

RECRUITING

Site Number - 1001, Morehead City

28601

RECRUITING

Site Number - 1026, Hickory

31904

RECRUITING

Site Number - 1020, Columbus

33016

RECRUITING

Site Number - 1008, Hialeah

33143

RECRUITING

Site Number - 1000, Miami

38119

RECRUITING

Site Number - 1017, Memphis

64110

RECRUITING

Site Number - 1004, Kansas City

65109

RECRUITING

Site Number - 1033, Jefferson City

66606

RECRUITING

Site Number - 1022, Topeka

73134

RECRUITING

Site Number - 1007, Oklahoma City

75031

RECRUITING

Site Number -1023, Irving

75039

RECRUITING

Site Number - 1021, Irving

75069

RECRUITING

Site Number - 1025, McKinney

76132

RECRUITING

Site Number - 1003, Fort Worth

78231

RECRUITING

Site Number - 1011, San Antonio

79935

RECRUITING

Site Number - 1002, El Paso

80045

RECRUITING

Site Number - 1013, Aurora

85710

RECRUITING

Site Number - 1015, Tucson

89511

RECRUITING

Site Number - 1012, Reno

94520

RECRUITING

Site Number -1014, Concord